Business Context and Reporting Period
This Form 8-K Current Report was filed by Glucotrack, Inc. (GCTK) on September 18, 2026, covering events occurring on September 14, 2026. The Company is incorporated in Delaware and trades on The Nasdaq Stock Market LLC. The filing addresses a significant corporate governance event involving the Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a personnel change and does not contain financial statements or operational metrics.
Material Changes
The primary material change reported is the immediate resignation of Paul V. Goode from the Board of Directors. Mr. Goode cited a potential conflict of interest between the Company and its subsidiary regarding ongoing discussions about the implementation of duties, rights, and obligations under the merger agreement with Lokahi Therapeutics, Inc.
Guidance, Outlook, and Risks
There is no forward-looking guidance or financial outlook provided in this filing. The Company noted that Mr. Goode was given the opportunity to submit a letter of disagreement regarding the Company's statements; no such letter was received at the time of filing. The filing highlights the risk of potential conflicts of interest arising from the post-merger integration discussions with Lokahi Therapeutics, Inc.
Key Facts for Investor Verification
- Paul V. Goode resigned from the Board of Directors effective September 14, 2026.
- The resignation was triggered by a perceived conflict of interest related to the merger agreement with Lokahi Therapeutics, Inc.
- The Company has filed Mr. Goode's resignation notice as Exhibit 17.1.
- No financial data or operational updates are included in this specific filing.